Skip to content
Screener

Organon OGN Nexplanon — Number of pending claims

Other product segments

Fosamax
$1.48K-14.8%
Nexplanon/Implanon NXT
$190.0%

Similar metrics at other companies

Sotera Health logo
SHCCalifornia — Number of pending claims
$150+87.5%
Sotera Health logo
SHCGeorgia — Number of pending claims
$500+63.9%
Sotera Health logo
SHCIllinois — Number of pending claims
$15-73.2%
Bausch + Lomb logo
BLCOCanada — Number of lawsuits pending
$20.0%
Bausch Health Companies logo
BHCCANADA — Number of lawsuits pending
$20.0%
Corteva logo
CTVANew Jersey & New York — Loss Contingency, Pending Claims, Number
$2

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:LossContingencyPendingClaimsNumber.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532

Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the “Fosamax Litigation”). As of March 31, 2026, the Fosamax Litigation comprises approximately 508 cases in Federal court, approximately 1,482 cases in New Jersey state court, one case in Pennsylvania state court and approximately 219 cases in California state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (“Femur Fractures”) associated with the use of Fosamax.

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's nexplanon — number of pending claims?
Organon (OGN) reported nexplanon — number of pending claims of $12 in Q1 2026.
How has Organon's nexplanon — number of pending claims changed year-over-year?
Organon's nexplanon — number of pending claims increased by 33.3% year-over-year, from $9 to $12.
What is the long-term trend for Organon's nexplanon — number of pending claims?
Over 4 years (2021 to 2025), Organon's nexplanon — number of pending claims has grown at a 20.5% compound annual growth rate (CAGR), from $19 to $40.
What does nexplanon — number of pending claims mean?
This metric tracks the number of unresolved legal claims filed against the company specifically related to the Nexplanon contraceptive implant. It serves as a primary indicator of the volume of potential liability and the ongoing legal exposure facing this specific product segment.

Ask your AI about Organon's nexplanon — number of pending claims.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude